BB-1701

DRUG2 trials

Sponsors

Bliss Biopharmaceutical (Hangzhou) Co., Ltd, Eisai Inc.

Conditions

Breast CancerLocally Advanced/Metastatic HER2 Positive Solid Tumors

Phase 1

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

CompletedNCT04257110

Bliss Biopharmaceutical (Hangzhou) Co., LtdLocally Advanced/Metastatic HER2 Positive Solid Tumors

Start: 2020-07-28End: 2024-12-31Updated: 2025-07-24

Phase 2

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

CompletedNCT06188559

Eisai Inc.Breast Cancer

Start: 2024-04-10End: 2026-03-18Updated: 2026-05-22

Related Papers

Abstract P4-10-23: Preclinical anti-tumor activity of BB-1701, a HER2-targeting eribulin conjugated ADC, in HER2-low breast cancer PDx models

Clinical Cancer Research2025-06-13

Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity

Antibody Therapeutics2024-06-259 citations

Updated safety and antitumor activity of BB-1701 from study 101 in the multiple dose level cohort of patients with locally advanced/metastatic HER2-low expressing breast cancer.

Journal of Clinical Oncology2024-06-012 citations

An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).

Journal of Clinical Oncology2024-06-011 citations

A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors.

Journal of Clinical Oncology2023-06-011 citations